From pro-re-nata to fixed-interval regimen: evolving real-world treatment paradigms in anti-VEGF therapy for neovascular AMD
- 29 January 2025
- journal article
- research article
- Published by Springer Nature in Eye
- Vol. 39 (7) , 1349-1355
Abstract
Objective To evaluate the impact of evolving treatment paradigms for neovascular age-related macular degeneration (nAMD) by comparing outcomes between two patient cohorts treated with different anti-vascular endothelial growth factor (anti-VEGF) regimens over a decade apart. Methods This retrospective cohort study included 200 treatment-naive nAMD patients divided into two cohorts. Cohort 1 (2009–2010) was treated with a pro re nata (PRN) regimen, involving three initial monthly injections followed by as-needed treatments based on monthly monitoring. Cohort 2 (2019–2021) received a fixed-interval regimen, consisting of three initial monthly injections followed by bimonthly maintenance doses. Primary outcomes included changes in best corrected visual acuity (BCVA) and central retinal thickness (CRT) at 12 months. Secondary outcomes included the number of injections, follow-up visits, and adherence to treatment schedules. Results Cohort 2 demonstrated significantly greater improvement in BCVA (+5.5 vs −2.0 ETDRS letters, p < 0.001) and CRT reduction (−101.7 vs −26.5 μm, p < 0.001) compared to Cohort 1. Patients in Cohort 2 received more injections (7.7 vs 4.8, p < 0.001) but required fewer monitoring visits (3.2 vs 5.1, p < 0.001). Adherence to treatment schedules was markedly higher in Cohort 2 (78% vs 0%, p < 0.001). Conclusions The transition from a PRN to a fixed-interval anti-VEGF regimen significantly improved visual and anatomical outcomes in nAMD patients. Fixed-interval regimens not only enhanced treatment efficacy but also optimized resource utilization, suggesting a superior approach for managing nAMD in a real-world clinical setting.Keywords
This publication has 27 references indexed in Scilit:
- Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical PracticeOphthalmology and Therapy, 2024
- TENAYA and LUCERNEOphthalmology, 2024
- Age-Related Macular DegenerationJAMA, 2024
- The ideal intravitreal injection setting: office, ambulatory surgery room or operating theatre? A narrative review and international surveyGraefe's Archive for Clinical and Experimental Ophthalmology, 2023
- Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year ResultsOphthalmology, 2023
- Practical guidance for imaging biomarkers in exudative age-related macular degenerationSurvey of Ophthalmology, 2023
- Efectividad de los regímenes tratar y extender vs. pro re nata para el tratamiento de degeneración macular neovascular vinculada a la edad: una comparación en un entorno realArchivos de la Sociedad Española de Oftalmología, 2020
- Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World StudiesAdvances in Therapy, 2019
- Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative studyGraefe's Archive for Clinical and Experimental Ophthalmology, 2019
- A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO StudyAmerican Journal of Ophthalmology, 2009